Development of technology based on specific metabolic regulation of neurodegenerative disease (Research Center for Metabolic Regulation Neurodegenerative disease)

摘要

Development of technology based on specific metabolic regulation of neurodegenerative disease (Research Center for Metabolic Regulation Neurodegenerative disease) Alzheimer’s disease (AD) is the most common form of demen- tia. It has been reported that metabolic dysregulation induces AD and in statistic study. Glucose resistance and insulin resistance, metabolic dysregulation marker, also showed not only in periph- eral organ but also in neuronal cells. Recently researchers proposed the term ‘Type-3-Diabetes’ for AD and pay attention that control of metabolic dysregulation as one of new approach for AD thera- peutic target. We have studied to control metabolic dysregulation by regulating energy metabolic receptor and furthermore we are aim for develop therapeutics to control AD and its diagnosis kit. Adiponectin and adiponectin receptor (AdipoR) stimulate energy metabolism in peripheral tissue. Especially, adiponectin receptor was expressed not only in peripheral tissue but in brain. We are trying to find the pathological and physiological role of AdipoR in AD. We are researching to find new drug candidates to atten- uate AD by analyzing the relation between AD and AdipoR via developing new biomarker, confirmed the effect of our drug candi- date in AD a and metabolic disorder animal model. Results showed that amyloid pathogenesis, inflammation, cell death and memory impairment was significantly recovered. And regulating insulin and AMPK brain-metabolic and peripheral metabolic dysregulation also recovered. This means activation of energy metabolism can control both AD and metabolic disorders. We had developed techniques for early diagnosis of AD through found new biomarker. This tech- nique can rapidly detect metabolites, amyloid beta oligomer and miRNA which are showing on early stage of AD and then visualize and quantify. With this technique, we contracted technical transfer with Phytos?. Our research project is extending from diagnosis to develop therapeutics and find cause of AD and outcomes have paid off as not only publication even patents. We expect that through our successful research project, we can handle AD becoming serious social problem in these days.